Soligenix, Inc. (SNGX) Analysts See $-0.22 EPS

March 14, 2018 - By Adrian Mccoy

 Soligenix, Inc. (SNGX) Analysts See $ 0.22 EPS

Analysts expect Soligenix, Inc. (NASDAQ:SNGX) to report $-0.22 EPS on March, 26.They anticipate $0.05 EPS change or 29.41 % from last quarter’s $-0.17 EPS. After having $-0.17 EPS previously, Soligenix, Inc.’s analysts see 29.41 % EPS growth. The stock decreased 0.50% or $0.01 during the last trading session, reaching $2.01. About 16,197 shares traded. Soligenix, Inc. (NASDAQ:SNGX) has declined 63.52% since March 14, 2017 and is downtrending. It has underperformed by 80.22% the S&P500.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $17.55 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

More notable recent Soligenix, Inc. (NASDAQ:SNGX) news were published by: which released: “Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis” on January 02, 2018, also with their article: “Soligenix Announces Reverse-Split in Preparation for Proposed Up-Listing of …” published on October 07, 2016, published: “Soligenix Announces Recent Accomplishments And Third Quarter 2017 Financial …” on November 06, 2017. More interesting news about Soligenix, Inc. (NASDAQ:SNGX) were released by: and their article: “Soligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell” published on August 30, 2017 as well as‘s news article titled: “Soligenix to Present at the 12th Annual International Partnering Conference …” with publication date: March 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: